Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab

The combination of ipilimumab plus nivolumab (I+N) has greatly improved outcomes in patients with intermediate or poor-risk untreated metastatic renal cell carcinoma (mRCC). However, little is known about the outcomes of patients with brain metastasis (BrM) treated with I+N. A search was performed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Landon C., Desai, Kunal, Wei, Wei, Kinsey, Emily N., Kao, Chester, George, Daniel J., Rini, Brian I., Ornstein, Moshe C., Zhang, Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438842/
https://www.ncbi.nlm.nih.gov/pubmed/34518292
http://dx.doi.org/10.1136/jitc-2021-003281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438842/
https://www.ncbi.nlm.nih.gov/pubmed/34518292
http://dx.doi.org/10.1136/jitc-2021-003281

Ejemplares similares